Literature DB >> 12705745

Positive margins in basal cell carcinoma: relationship to clinical features and recurrence risk. A retrospective study of 248 patients.

E Nagore1, C Grau, J Molinero, J M Fortea.   

Abstract

BACKGROUND: Incomplete resection of a basal cell carcinoma does not necessarily imply tumour recurrence.
OBJECTIVE: The purpose of our study was to determine the clinical features most often associated with positive surgical margins and to establish whether positive margins effectively imply tumour recurrence.
METHODS: We did a retrospective evaluation of 273 basal cell carcinomas in a total of 248 subjects. For each case, data regarding tumour location, sex, histological type and the presence or absence of affected surgical margins were collected. Follow-up was available in 151 cases.
RESULTS: Positive margins were most often observed in facial lesions, particularly in the nasal and perioral areas, and for morphoeic histological types. Tumours with margin involvement exhibited a higher recurrence rate (26%) than those with free margins (14%) over a 5-year follow-up period.
CONCLUSIONS: Individualized management, with special considerations depending on tumour location and histological type, is needed to treat basal cell carcinomas and cases with affected margins. Re-excision, preferably with Mohs' surgery, is advised in the latter as recurrences are much more complicated to treat. Furthermore, all cases need adequate follow-up, even in cases with unaffected surgical margins.

Entities:  

Mesh:

Year:  2003        PMID: 12705745     DOI: 10.1046/j.1468-3083.2003.00535.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  21 in total

Review 1.  [Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma].

Authors:  R-M Szeimies; S Karrer; H Bäcker
Journal:  Hautarzt       Date:  2005-05       Impact factor: 0.751

2.  Expression of matrix metalloproteinase-1, -9, -13, and tissue inhibitor of metalloproteinases-1 in basal cell carcinomas of the eyelid.

Authors:  Zornitsa I Zlatarova; Ekaterina B Softova; Klara G Dokova; Elisabeth M Messmer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-09-01       Impact factor: 3.117

3.  A reliable frozen section technique for basal cell carcinomas of the head and neck.

Authors:  Wisam Menesi; Edward W Buchel; Thomas Je Hayakawa
Journal:  Plast Surg (Oakv)       Date:  2014       Impact factor: 0.947

4.  Staged-surgery with permanent pathology for the management of high-risk nonmelanoma skin cancer of the nose.

Authors:  Görkem Eskiizmir; Gülsüm Gençoğlan; Peyker Temiz; Zafer Hirçin; Aylin Ermertcan
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-07-08       Impact factor: 2.503

Review 5.  [Skin tumours of the facial area].

Authors:  M Braun-Falco
Journal:  HNO       Date:  2009-04       Impact factor: 1.284

Review 6.  Pharmacological treatments for basal cell carcinoma.

Authors:  Seongmu Lee; Dinesh Selva; Shyamala C Huilgol; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Management of superficial basal cell carcinoma: focus on imiquimod.

Authors:  Beverly Raasch
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-06-11

8.  Incomplete removal of basal cell carcinoma: what is the value of further surgery?

Authors:  Shiralee S Patel; Sandeep H Cliff; Peter Ward Booth
Journal:  Oral Maxillofac Surg       Date:  2012-08-07

9.  Clinicopathological Factors Associated with Incomplete Excision of High-risk Basal Cell Carcinoma.

Authors:  Hannah Ceder; Annie Ekström; Lajla Hadzic; John Paoli
Journal:  Acta Derm Venereol       Date:  2021-07-13       Impact factor: 3.875

10.  Pre-surgical high resolution ultrasound of facial basal cell carcinoma: correlation with histology.

Authors:  Francisco Bobadilla; Ximena Wortsman; Carla Muñoz; Laura Segovia; Miguel Espinoza; Gregor B E Jemec
Journal:  Cancer Imaging       Date:  2008-09-22       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.